Xtant Medical Holdings Inc (XTNT) Stock Analysis
Verdict: WATCH (do not buy)
BioHorizons partnership adds dental revenue optionality, but persistent TTM losses and recent EPS misses keep dilution risks elevated.
Investment score: 43/100
Analysis as of
Is Xtant Medical Holdings Inc stock worth reviewing? AI model thesis
The model score of 43/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 42/100 (weight 20%)
- Financial Health: 48/100 (weight 15%)
- Technical Momentum: 38/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 68/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Xtant Medical Holdings Inc opportunities and risks
What speaks for XTNT
- BioHorizons exclusive partnership unlocks adjacent dental and oral-maxillofacial markets.
What speaks against XTNT
- Dilution risk driven by recurring unprofitability and equity capital raises.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| XTNT | n/a | 0.5x | n/a | 59.4% | -10.2% | -1.3% |
| EMBC | 3.4x | 0.3x | 5.8x | 59.9% | 8.6% | 54.9% |
| OSUR | n/a | 2.2x | n/a | 41.4% | -43.7% | -19.4% |
| ACU | 24.5x | 1.1x | 12.8x | 40.1% | 4.6% | 6.4% |
| UTMD | 22.2x | 6.4x | 15.8x | 54.9% | 29.0% | 4.9% |
| SKYA | n/a | 24.1x | n/a | 106.0% | -15914.9% | -26.8% |
| Peer median | 3.4x | 2.2x | 5.8x | 54.9% | 4.6% | 4.9% |
Frequently asked questions about Xtant Medical Holdings Inc (XTNT)
Is XTNT stock a good investment?
The cached TradeMates AI model rates Xtant Medical Holdings Inc as WATCH (do not buy) with an investment score of 43/100. The model score of 43/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is XTNT stock a buy?
The TradeMates model verdict for XTNT is WATCH (do not buy) with an investment score of 43/100. Treat this as a model signal to review, not a personal buy recommendation.